US-based Illumina has launched its TruSight One Sequencing Panel, a broadest sequencing panel that targets 4,813 genes with known associated clinical phenotypes.
Laboratories can use this panel to expand existing menus, streamline workflows, or create an entire portfolio of sequencing options.
As a result, they can increase productivity, reduce handling errors, decrease laboratory costs, and provide consistent reports and results.
TruSight One comes with VariantStudio software, a simple, yet powerful tool for analysis, classification, and reporting of genomic variants.
Using VariantStudio, labs can quickly and accurately extract and report on only the disease-relevant information of interest.
To coincide with the introduction of the TruSight One Sequencing Panel, VariantStudio will offer new features that expand annotation and filtering capabilities.
These features include support for enabling family-based filtering (mother, father, child, and siblings), providing variant classifications, and generating ready-to-use reports.
In addition, the TruSight One Sequencing Panel can be used to create dozens of "virtual subpanels" to fit the needs of any clinical researcher seeking to understand the genetic basis of disease.
Illumina's Translational and Consumer Genomics business senior vice president and general manager Matt Posard said Illumina is moving in the direction of one simple workflow which will drastically reduce the turnaround time from sample-to-report.
"With the TruSight One Sequencing Panel and enhancements to VariantStudio, Illumina is providing clinical researchers with a simple, cost-effective solution that replaces small sequencing panels with a single robust platform." Posard added.
